Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Delaney Dennis R

Delaney Dennis R boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,343 shares of the pharmaceutical company’s stock after acquiring an additional 440 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 1.7% of Delaney Dennis R’s investment portfolio, making the stock its 24th biggest position. Delaney Dennis R’s holdings in Vertex Pharmaceuticals were worth $3,269,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in VRTX. Brighton Jones LLC boosted its holdings in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares during the period. GAMMA Investing LLC boosted its stake in shares of Vertex Pharmaceuticals by 25.1% in the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock valued at $2,425,000 after buying an additional 1,005 shares during the period. NorthCrest Asset Manangement LLC grew its position in shares of Vertex Pharmaceuticals by 7.4% during the first quarter. NorthCrest Asset Manangement LLC now owns 1,389 shares of the pharmaceutical company’s stock worth $673,000 after buying an additional 96 shares in the last quarter. Salem Investment Counselors Inc. increased its stake in shares of Vertex Pharmaceuticals by 23.6% during the first quarter. Salem Investment Counselors Inc. now owns 320 shares of the pharmaceutical company’s stock worth $155,000 after buying an additional 61 shares during the period. Finally, CVA Family Office LLC raised its holdings in Vertex Pharmaceuticals by 11.5% in the first quarter. CVA Family Office LLC now owns 427 shares of the pharmaceutical company’s stock valued at $207,000 after acquiring an additional 44 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $407.79 on Monday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The company has a market capitalization of $104.55 billion, a price-to-earnings ratio of 29.15 and a beta of 0.43. The stock has a fifty day moving average of $393.91 and a two-hundred day moving average of $438.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the prior year, the business posted ($12.83) earnings per share. The firm’s revenue for the quarter was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Bruce I. Sachs purchased 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on VRTX. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price target for the company from $458.00 to $456.00 in a research note on Thursday, September 25th. Scotiabank decreased their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Royal Bank Of Canada cut their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 5th. Finally, Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a report on Wednesday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $494.38.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.